Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$8.96 +2.3%	$10.08	$6.01 ▼ $11.31	$1.87B	1.04	3.91 million shs	3.32 million shs
CBMG Cellular Biomedicine Group		$19.68	$11.48 ▼ $19.75	$384.69M	1.35	129,776 shs	8,375 shs
DTIL Precision BioSciences	$4.64 +4.3%	$4.80	$3.61 ▼ $11.09	$51.46M	1.43	361,288 shs	179,730 shs
HARP Harpoon Therapeutics	$23.01	$22.89	$3.11 ▼ $23.21	$389.61M	2.11	1.52 million shs	N/A
VYGR Voyager Therapeutics	$3.43 -1.7%	$3.20	$2.64 ▼ $9.55	$189.82M	0.85	476,128 shs	491,549 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	0.00%	-2.07%	-15.53%	+24.43%	+22.52%
CBMG Cellular Biomedicine Group	0.00%	0.00%	0.00%	0.00%	0.00%
DTIL Precision BioSciences	0.00%	+1.71%	-9.18%	-0.22%	-56.07%
HARP Harpoon Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
VYGR Voyager Therapeutics	0.00%	+6.40%	+5.76%	+9.40%	-60.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCRX BioCryst Pharmaceuticals	4.2053 of 5 stars	4.5	1.0	0.0	4.2	1.4	1.7	0.6
CBMG Cellular Biomedicine Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	4.2813 of 5 stars	3.5	1.0	0.0	4.6	3.1	1.7	1.3
HARP Harpoon Therapeutics	0.7533 of 5 stars	0.0	0.0	0.0	4.7	0.6	2.5	0.0
VYGR Voyager Therapeutics	3.9697 of 5 stars	3.6	2.0	0.0	4.6	2.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.90	Moderate Buy	$16.70	86.38% Upside
CBMG Cellular Biomedicine Group	0.00	N/A	N/A	N/A
DTIL Precision BioSciences	3.00	Buy	$47.00	912.93% Upside
HARP Harpoon Therapeutics	0.00	N/A	N/A	N/A
VYGR Voyager Therapeutics	3.13	Buy	$13.39	290.38% Upside

Current Analyst Ratings Breakdown

Latest DTIL, CBMG, BCRX, VYGR, and HARP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	BCRX BioCryst Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $18.00
6/25/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
5/21/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/7/2025	BCRX BioCryst Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $11.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $17.00
5/6/2025	BCRX BioCryst Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/29/2025	BCRX BioCryst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$20.00

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$450.71M	4.16	N/A	N/A	($2.30) per share	-3.90
CBMG Cellular Biomedicine Group	$340K	0.00	N/A	N/A	$2.89 per share	0.00
DTIL Precision BioSciences	$68.70M	0.75	N/A	N/A	$6.87 per share	0.68
HARP Harpoon Therapeutics	$37.34M	10.43	N/A	N/A	$1.63 per share	14.12
VYGR Voyager Therapeutics	$80M	2.37	N/A	N/A	$5.49 per share	0.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	-$88.88M	-$0.26	N/A	N/A	2.50	-10.62%	N/A	-11.06%	8/4/2025 (Estimated)
CBMG Cellular Biomedicine Group	-$49.98M	N/A	N/A	N/A	N/A	N/A	-144.80%	-61.68%	N/A
DTIL Precision BioSciences	$7.17M	-$2.01	N/A	N/A	N/A	-42.99%	-69.26%	-29.30%	7/30/2025 (Estimated)
HARP Harpoon Therapeutics	-$67.73M	-$8.76	N/A	N/A	N/A	-81.68%	-893.55%	-45.98%	N/A
VYGR Voyager Therapeutics	-$65M	-$1.46	N/A	N/A	N/A	-126.49%	-27.36%	-21.06%	8/5/2025 (Estimated)

Latest DTIL, CBMG, BCRX, VYGR, and HARP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	DTIL Precision BioSciences	-$0.09	N/A	N/A	N/A	$6.27 million	N/A
8/5/2025	Q2 2025	VYGR Voyager Therapeutics	-$0.48	N/A	N/A	N/A	$9.50 million	N/A
8/4/2025	Q2 2025	BCRX BioCryst Pharmaceuticals	$0.02	N/A	N/A	N/A	$149.59 million	N/A
5/15/2025	Q1 2025	DTIL Precision BioSciences	-$0.43	-$2.21	-$1.78	-$2.21	$5.00 million	$0.03 million
5/6/2025	Q1 2025	VYGR Voyager Therapeutics	-$0.35	-$0.53	-$0.18	-$0.53	$13.55 million	$6.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CBMG Cellular Biomedicine Group	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
HARP Harpoon Therapeutics	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.93	2.88
CBMG Cellular Biomedicine Group	N/A	0.47	0.47
DTIL Precision BioSciences	0.45	6.62	6.62
HARP Harpoon Therapeutics	N/A	1.89	1.89
VYGR Voyager Therapeutics	N/A	6.10	6.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
CBMG Cellular Biomedicine Group	21.98%
DTIL Precision BioSciences	37.99%
HARP Harpoon Therapeutics	74.01%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	4.80%
CBMG Cellular Biomedicine Group	8.50%
DTIL Precision BioSciences	4.00%
HARP Harpoon Therapeutics	17.00%
VYGR Voyager Therapeutics	4.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	209.25 million	199.21 million	Optionable
CBMG Cellular Biomedicine Group	217	19.48 million	N/A	Optionable
DTIL Precision BioSciences	200	11.09 million	10.64 million	No Data
HARP Harpoon Therapeutics	53	16.93 million	14.05 million	Optionable
VYGR Voyager Therapeutics	100	55.34 million	52.83 million	Optionable

DTIL, CBMG, BCRX, VYGR, and HARP Headlines

Recent News About These Companies

UK awards AirTanker network node upgrade for Voyager

July 11 at 10:28 AM | janes.comJ

Voyager 1 & 2 Could Be Detected From Almost A Light-Year Away With Our Current Technology

July 10, 2025 | msn.com

Brokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) Price Target at $13.39

July 8, 2025 | americanbankingnews.com

RNLI thanks Condor Voyager for helping save French yacht crew in 'challenging conditions'

July 7, 2025 | itv.comI

Atlas Announces New Canadian Arctic Expedition Aboard World Voyager

July 6, 2025 | cruiseindustrynews.comC

With Alipay+ Voyager, Ant International provides an AI travel assistant in Asian E-Wallets

July 5, 2025 | travelmole.comT

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of "Buy" from Brokerages

July 5, 2025 | marketbeat.com

Ant International launches Alipay+ Voyager, an AI-powered travel assistant inside e-wallets

July 3, 2025 | walastech.comW

VYGR Voyager Therapeutics, Inc. - Seeking Alpha

June 25, 2025 | seekingalpha.com

Major Security Breach at RAF Brize Norton Sees Protesters Spray Voyager Aircraft With Paint

June 20, 2025 | theaviationist.comT

Protesters Vandalize RAF Voyager Tankers In Palestine Protest

June 20, 2025 | aviationweek.comA

Voyager Technologies Soars with IPO Success

June 14, 2025 | devdiscourse.comD

Space Tech Ventures Surge: Voyager's IPO Success and Starlink's Swiss Expansion

June 12, 2025 | devdiscourse.comD

Voyager Technologies Rises in Debut, Signaling Improving IPO Market

June 12, 2025 | msn.com

Voyager soars 82% on first day of trading as defense tech booms

June 12, 2025 | msn.com

Investor demand for Voyager’s stock keeps growing, despite a mixed history for space-tech IPOs

June 11, 2025 | msn.com

Voyager Technologies' Shares More Than Double in NYSE Debut

June 11, 2025 | marketwatch.com

Voyager Technologies Shares Soar In Market Debut

June 11, 2025 | news.crunchbase.comN

Space tech firm Voyager valued at $3.8 billion as shares surge in NYSE debut

June 11, 2025 | aol.comA

Voyager raises $383 million from upsized IPO

June 11, 2025 | spacenews.comS

Space and defense tech firm Voyager raises $382.8 million in IPO

June 11, 2025 | fastcompany.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL, CBMG, BCRX, VYGR, and HARP Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.96 +0.20 (+2.28%)

Closing price 04:00 PM Eastern

Extended Trading

$8.94 -0.02 (-0.17%)

As of 04:33 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Cellular Biomedicine Group NASDAQ:CBMG

Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.

Precision BioSciences NASDAQ:DTIL

$4.64 +0.19 (+4.27%)

Closing price 04:00 PM Eastern

Extended Trading

$4.58 -0.05 (-1.19%)

As of 04:53 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Harpoon Therapeutics NASDAQ:HARP

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

Voyager Therapeutics NASDAQ:VYGR

$3.43 -0.06 (-1.72%)

Closing price 04:00 PM Eastern

Extended Trading

$3.42 -0.01 (-0.29%)

As of 04:54 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time